There are currently 22 clinical trials in Sandy Springs, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Advanced Medical Reserarch, PC, WR-Mount Vernon Clinical Research, LLC, Mount Vernon Clinical Research, LLC and Advanced Medical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Site 90, Sandy Springs, Georgia
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/26/2025
Locations: Thomas Eye Group, Sandy Springs, Georgia
Conditions: Diabetic Retinopathy
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Thomas Eye Group, Sandy Springs, Georgia
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Thomas Eye Group, Sandy Springs, Georgia
Conditions: Epiretinal Membrane
Register for Updates
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090
Recruiting
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia
Conditions: Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Register for Updates
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523
Recruiting
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/02/2025
Locations: Ascendis Investigational Site, Sandy Springs, Georgia
Conditions: Growth Hormone Deficiency
Register for Updates
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672
Recruiting
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/01/2025
Locations: Ascendis Investigational Site, Sandy Springs, Georgia
Conditions: Growth Hormone Deficiency
Register for Updates
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671
Recruiting
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/09/2025
Locations: Clinical Site, Sandy Springs, Georgia
Conditions: Hidradenitis Suppurativa
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Thomas Eye Group, P.C., Sandy Springs, Georgia
Conditions: Neurotrophic Keratopathy
Register for Updates
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
NCT05303636
Recruiting
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and a... Read More
Gender:
FEMALE
Ages:
Between 14 years and 45 years
Trial Updated:
06/15/2023
Locations: M3 Wake Research, Inc., Sandy Springs, Georgia
Conditions: Change in Bone Mineral Density, Bone Loss
Register for Updates